Sugimoto, Toshitsugu
Inoue, Daisuke http://orcid.org/0000-0002-8311-0787
Maehara, Masayuki
Oikawa, Ichiro
Shigematsu, Takashi
Nishizawa, Yoshiki
Funding for this research was provided by:
Joint Development Program of EA Pharma Co., Ltd. and Takeda Pharmaceutical Co., Ltd.
Article History
Received: 3 July 2018
Accepted: 31 October 2018
First Online: 6 December 2018
Compliance with ethical standards
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
: Dr. Toshitsugu Sugimoto has received research grants from Eli Lilly Japan, Taisho Toyama Pharmaceutical, Chugai Pharmaceutical, Daiichi-Sankyo Co., Astellas Pharma, and Eisai, as well as consulting fee from Asahi-Kasei Pharma Co. Dr. Daisuke Inoue reports personal fees from EA Pharma and grants from Astellas Pharma, Asahi-Kasei Pharma, Chugai Pharmaceutical, Daiichi-Sankyo Co., EA Pharma, Eli Lilly Japan, Eisai, Pfizer, Ono Pharmaceutical, Taisho Toyama Pharmaceutical, Takeda Pharmaceutical, and Teijin Pharma, outside the submitted work. Mr. Masayuki Maehara and Mr. Ichiro Oikawa are full-time employees of EA Pharma. Dr. Takashi Shigematsu has received consultant fees from EA pharma and Takeda pharmaceutical. Dr. Yoshiki Nishizawa has no conflicts of interest to disclose.